Hosted on MSN

Roche says experimental drug helped slow disability in progressive multiple sclerosis study

Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib. Fenebrutinib is an ...
Medical Xpress

Oral bacterium tied to disability severity in multiple sclerosis

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders through chronic inflammation. However, its role in multiple sclerosis, a ...
Nasdaq

Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in ...